Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Thermo Fisher Scientific Inc (NYSE: TMO) closed the day trading at $484.79 up 1.55% from the previous closing price of $477.41. In other words, the price has increased by $1.55 from its previous closing price. On the day, 2.05 million shares were traded. TMO stock price reached its highest trading level at $486.98 during the session, while it also had its lowest trading level at $478.715.
Ratios:
For a better understanding of TMO, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 28.63 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.67. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.93. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.65.
On July 11, 2025, Scotiabank Upgraded its rating to Sector Outperform which previously was Sector Perform but kept the price unchanged to $590.
UBS Downgraded its Buy to Neutral on July 09, 2025, while the target price for the stock was maintained at $460.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 06 ’25 when CASPER MARC N sold 10,000 shares for $451.82 per share. The transaction valued at 4,518,216 led to the insider holds 115,174 shares of the business.
CASPER MARC N sold 8,000 shares of TMO for $3,635,567 on Aug 07 ’25. The Chairman & CEO now owns 115,174 shares after completing the transaction at $454.45 per share. On Aug 07 ’25, another insider, CASPER MARC N, who serves as the Officer of the company, bought 8,000 shares for $454.86 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMO now has a Market Capitalization of 183062528000 and an Enterprise Value of 211992576000. As of this moment, Thermo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 28.06, and their Forward P/E ratio for the next fiscal year is 19.88. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.91. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.24 while its Price-to-Book (P/B) ratio in mrq is 3.62. Its current Enterprise Value per Revenue stands at 4.906 whereas that against EBITDA is 19.596.
Stock Price History:
The Beta on a monthly basis for TMO is 0.75, which has changed by -0.19695538 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, TMO has reached a high of $627.88, while it has fallen to a 52-week low of $385.46. The 50-Day Moving Average of the stock is 12.51%, while the 200-Day Moving Average is calculated to be -0.35%.
Shares Statistics:
Over the past 3-months, TMO traded about 2.81M shares per day on average, while over the past 10 days, TMO traded about 2184090 shares per day. A total of 377.61M shares are outstanding, with a floating share count of 376.98M. Insiders hold about 0.17% of the company’s shares, while institutions hold 91.35% stake in the company. Shares short for TMO as of 1753920000 were 3709322 with a Short Ratio of 1.32, compared to 1751241600 on 4413729. Therefore, it implies a Short% of Shares Outstanding of 3709322 and a Short% of Float of 0.98.
Dividends & Splits
TMO’s forward annual dividend rate is 1.64, up from 1.64 a year ago. Against a Trailing Annual Dividend Yield of 0.0034352024The stock’s 5-year Average Dividend Yield is 0.23. The current Payout Ratio is 9.43% for TMO, which recently paid a dividend on 2025-06-13 with an ex-dividend date of 2025-09-15. Stock splits for the company last occurred on 1996-06-06 when the company split stock in a 3:2 ratio.
Earnings Estimates
The market rating for Thermo Fisher Scientific Inc (TMO) is a result of the insights provided by 21.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $6.51, with high estimates of $6.93 and low estimates of $6.22.
Analysts are recommending an EPS of between $22.62 and $22.29 for the fiscal current year, implying an average EPS of $22.49. EPS for the following year is $24.47, with 27.0 analysts recommending between $25.87 and $23.76.
Revenue Estimates
18 analysts predict $10.9B in revenue for the current quarter. It ranges from a high estimate of $11B to a low estimate of $10.85B. As of the current estimate, Thermo Fisher Scientific Inc’s year-ago sales were $10.6BFor the next quarter, 18 analysts are estimating revenue of $11.76B. There is a high estimate of $11.95B for the next quarter, whereas the lowest estimate is $11.5B.
A total of 25 analysts have provided revenue estimates for TMO’s current fiscal year. The highest revenue estimate was $44.06B, while the lowest revenue estimate was $43.6B, resulting in an average revenue estimate of $43.87B. In the same quarter a year ago, actual revenue was $42.88BBased on 25 analysts’ estimates, the company’s revenue will be $45.97B in the next fiscal year. The high estimate is $47.58B and the low estimate is $45.24B.
